Making the RIGHT Treatment Decision

Your patient’s well-being and quality of life are most important.

 

After a positive/malignant prostate biopsy result, making a confident and individualized treatment decision may involve weighing different factors.

If your patient was diagnosed with early-stage prostate cancer, there are often multiple options to consider. Not every patient necessarily needs aggressive treatment. For many men, active surveillance may be the right treatment decision.

Some aspects to consider before proceeding with aggressive treatment include:

  • Age
  • General health
  • Side effects, especially those affecting daily life activities
  • Your patient’s desires/opinions (as well as family/caregivers)
  • Aggressiveness of your patient’s specific disease
    • Gleason Scores 3+3 and 3+4: ProMark can provide a personalized risk of disease aggressiveness, providing reliable, standalone information to inform your treatment decision
    • For Atypical/HGPIN results: PTEN/ERG can further predict your patient’s disease aggressiveness

Aggressive treatments, such as prostatectomy, radiation therapy, chemotherapy, and hormone therapy, are often accompanied by the risk of unpleasant and unwanted side effects, some of them permanent and life-altering. Although the right option for some patients, active treatment may not be the best choice for all. 

Gain an advantage by accessing as much information as possible about your individual patient to make the best possible and most confident treatment decision.
 

Is Active Surveillance the right decision?
ProMark can help


  Next: Active Surveillance
ProMark: Proteomics Prognostic Test for Prostate Cancer

ProMark, a first-of-its-kind  proteomic prognostic test for biopsy Gleason Scores 3+3 and 3+4.

Gain CONFIDENCE for better treatment decisions.

                                                                  LEARN MORE
 




Improve your biopsy decisions.
Reduce the number of unnecessary repeat biopsies.

                                                                  LEARN MORE